Prospective iNO Administration ("After" Group)
PreclinicalSmall molecule
Prospective iNO Administration ("After" Group) is one of 38 small molecule programs targeting Liver Transplant. It is currently in Preclinical.
1
Indications
1
Total Trials
1
Active Trials
37
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
353 competitors in Liver Transplant
#DrugCompanyPhaseTrials
1Vemlidy
GileadPreclinical
Cysteine Hydrochloride
NovartisPreclinical
Octreotide
Johnson & JohnsonPreclinical
Lenvima
EisaiPreclinical
Prostigmin
Merck & Co.Preclinical
Myfortic
NovartisPreclinical
Precedex
MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.
Preclinical
Myfortic
NovartisPreclinical
Cyklokapron
AAmring
Preclinical
Cytovene
EExela Pharma Sciences, LLC.
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Liver Transplant1 trial
Effect Inhaled Nitric Oxide in Adult Liver Transplant
Not yet recruiting·LLondon Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's·N/A·NCT07125443·260 enrolled
Sources
References
- [1]
- [2]
- [3]
- [4]
Details